Some will say that immunotherapy became a household word in 2015. That’s in large part to the significant number of FDA approvals. Checkpoint blockade—called so because they “release the brakes” on the immune system, allowing it to mount a stronger and more effective attack against cancer—was FDA approved for melanoma, lung cancer, and kidney cancer. A new type of immunotherapy—oncolytic virus therapy—got approval in October to treat melanoma. And there are now more than 20 approved antibody-based drugs, including new immunotherapies for neuroblastoma and multiple myeloma. Let’s take a look!
2015 was a great year for cancer immunotherapy, and we expect it to be the same in 2016 and beyond, with more treatments—therapeutic vaccines, CAR T cell therapy—joining the list. Stay tuned!
CRI Scientific Advisory Council Member Elected NAI Fellow
Read Previous Article
Immunotherapy Approvals in 2015
Read Next Article
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
This July for Sarcoma Awareness Month, we look at new research, new treatments, and how we’re working toward a future immune to sarcoma.
CRI-Chordoma Foundation CLIP Investigator Dr. Cassian Yee is exploring how to design cell therapies for patients with a rare type of sarcoma.